Share This Author
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
- Y. Goekoop-Ruiterman, J. D. de Vries-Bouwstra, B. Dijkmans
- MedicineArthritis and rheumatism
- 1 November 2005
In patients with early RA, initial combination therapy including either prednisone or infliximab resulted in earlier functional improvement and less radiographic damage after 1 year than did sequential monotherapy or step-up combination therapy.
Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes.
- J. Wessels, J. D. de Vries-Bouwstra, H. Guchelaar
- Medicine, BiologyArthritis and rheumatism
- 1 April 2006
Patients with MTHfr 1298AA and MTHFR 677CC showed greater clinical improvement with MTX, whereas only the MTH FR 1298C allele was associated with toxicity, and MthFR genotypes may help determine which patients will benefit most from MTX treatment.
Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis
The association between joint damage progression and both hand and generalised BMD loss in RA suggests common pathways between these processes, with hand B MD loss occurring earlier in the disease course than generalised bMD loss.
A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study
The matrix model visualises the risk of RRP for subpopulations of patients with recent-onset RA if treated dynamically with initial monotherapy or combination therapy, and was associated with a markedly reduced risk ofRRP.
DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis
- Y. Goekoop-Ruiterman, J. de Vries-Bouwstra, B. Dijkmans
- MedicineAnnals of the rheumatic diseases
- 20 January 2009
In patients with recent-onset rheumatoid arthritis receiving traditional treatment, systematic DAS-driven therapy results in significantly better clinical improvement and possibly improves the suppression of joint damage progression.
Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
Initial combination therapy with infliximab for patients with recent-onset active RA resulted in significantly better quality of life than other strategies and should be preferred, according to the friction cost method.
Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients.
Frequency of two SNPs in FPGS and GGH genes and their associated with response to MTX in rheumatoid arthritis patients treated with MTX monotherapy are suggested not to be clinically important for MTX treatment outcome.
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis
- S. M. van der Kooij, Y. Goekoop-Ruiterman, C. Allaart
- Medicine, PsychologyAnnals of the rheumatic diseases
- 28 July 2008
In patients with recent-onset active RA, drug-free remission was achieved in up to 18% of patients, and DAS-driven treatment maintained clinical and functional improvement, independent of the treatment strategy.
Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.
- C. Allaart, Y. Goekoop-Ruiterman, J. D. de Vries-Bouwstra, F. Breedveld, B. Dijkmans
- MedicineClinical and experimental rheumatology
- 1 November 2006
In patients with early, active RA, remarkable clinical improvement and suppression of joint damage progression can be achieved with frequent, objectively steered treatment adjustments.
Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial
A lower DAS is associated with lower BP in patients with recent-onset rheumatoid arthritis, and an additional decrease in BP was observed in patients treated with infliximab.